The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Psoriasis: Which therapy for which patient
Open accessAbstract
Despite the availability of several new systemic agents for psoriasis treatment, choosing the right therapy in certain patient populations can be challenging. There are few up-to-date reviews on systemic drugs for moderate to severe psoriasis in pregnant and pediatric patients and in patients with concomitant chronic infections, such as hepatitis, HIV, and latent tuberculosis. These groups are usually excluded from clinical trials, and much of the available evidence is based on anecdotal case reports and case series. As a chronic disease, psoriasis requires long-term treatment, and there are concerns of adverse maternal-fetal outcomes, long-term side effects in children, and the reactivation of latent infections with the use of systemic agents in these patients. The second article in this continuing medical education series provides insights for choosing appropriate systemic agents for treating moderate to severe psoriasis in pregnant and pediatric patients and in the setting of chronic infections, such as hepatitis, HIV, and latent tuberculosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874
Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
Lichtenstein, G. R., Feagan, B. G., Cohen, R. D., Salzberg, B. A., Diamond, R. H., Chen, D. M., Pritchard, M. L., & Sandborn, W. J. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.03.002 · Cited by 905
(1994) · The Lancet · doi:10.1016/s0140-6736(94)91766-3 · Cited by 656
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B., Gottlieb, A. B., Koo, J. Y. M., Lebwohl, M., Lim, H. W., et al. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.03.027 · Cited by 558
Self-citationCyclosporin A Suppresses Replication of Hepatitis C Virus Genome in Cultured Hepatocytes
Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M., & Shimotohno, K. (2003) · Hepatology · doi:10.1053/jhep.2003.50449 · Cited by 510
PREGNANCY OUTCOME AFTER CYCLOSPORINE THERAPY DURING PREGNANCY: A META-ANALYSIS1
Bar Oz, B., Hackman, R., Einarson, T., & Koren, G. (2001) · Transplantation · doi:10.1097/00007890-200104270-00006 · Cited by 433
Cheent, K., Nolan, J., Shariq, S., Kiho, L., Pal, A., & Arnold, J. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2010.05.001 · Cited by 407
Nast, A., Gisondi, P., Ormerod, A. D., Saiag, P., Smith, C., Spuls, P. I., Arenberger, P., Bachelez, H., Barker, J., Dauden, E., et al. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13354 · Cited by 399
Etanercept Treatment for Children and Adolescents with Plaque Psoriasis
Paller, A. S., Siegfried, E. C., Langley, R. G., Gottlieb, A. B., Pariser, D., Landells, I., Hebert, A. A., Eichenfield, L. F., Patel, V., Creamer, K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa066886 · Cited by 391
A Comparative Study of Pediatric Onset Psoriasis with Adult Onset Psoriasis
Raychaudhuri, S. P., & Gross, J. (2000) · Pediatric Dermatology · doi:10.1046/j.1525-1470.2000.01746.x · Cited by 313
Latent Tuberculosis Infection in the United States
Horsburgh, C. R., & Rubin, E. J. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1005750 · Cited by 311
Harper, J. I., Ahmed, I., Barclay, G., Lacour, M., Hoeger, P., Cork, M. J., Finlay, A. Y., Wilson, N. J. E., Graham-Brown, R. A. C., Sowden, J. M., et al. (2000) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2000.03241.x · Cited by 281
Pérez-Alvarez, R., Díaz-Lagares, C., García-Hernández, F., Lopez-Roses, L., Brito-Zerón, P., Pérez-de-Lis, M., Retamozo, S., Bové, A., Bosch, X., Sanchez-Tapias, J.-M., et al. (2011) · Medicine · doi:10.1097/md.0b013e3182380a76 · Cited by 276
Vasiliauskas, E. A., Church, J. A., Silverman, N., Barry, M., Targan, S. R., & Dubinsky, M. C. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.07.018 · Cited by 268
CARTER, J. D., LADHANI, A., RICCA, L. R., VALERIANO, J., & VASEY, F. B. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.080545 · Cited by 256
Zein, N. N., & for the Etanercept Study Group (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.11.025 · Cited by 248
Problems encountered during anti-tumour necrosis factor therapy
Desai, S. B., & Furst, D. E. (2006) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2006.06.002 · Cited by 221
Bennett, D. E., Courval, J. M., Onorato, I., Agerton, T., Gibson, J. D., Lambert, L., McQuillan, G. M., Lewis, B., Navin, T. R., & Castro, K. G. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-057oc · Cited by 209
The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease
Cepeda, E. J., Williams, F. M., Ishimori, M. L., Weisman, M. H., & Reveille, J. D. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.081513 · Cited by 199
Cyclosporine in severe childhood atopic dermatitis: A multicenter study
Berth-Jones, J., Finlay, A. Y., Zaki, I., Tan, B., Goodyear, H., Lewis-Jones, S., Cork, M. J., Bleehen, S. S., Salek, M. S., Allen, B. R., et al. (1996) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(96)90281-9 · Cited by 195
Doherty, S. D., Van Voorhees, A., Lebwohl, M. G., Korman, N. J., Young, M. S., & Hsu, S. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.03.023 · Cited by 171
Self-citationConsensus Guidelines for the Management of Plaque Psoriasis
Hsu, S. (2012) · Archives of Dermatology · doi:10.1001/archdermatol.2011.1410 · Cited by 161
Chiu, H., Chen, C., Wu, M., Cheng, Y. ‐., & Tsai, T. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12461 · Cited by 144
Vesga, L., Terdiman, J. P., & Mahadevan, U. (2005) · Gut · doi:10.1136/gut.2005.065417 · Cited by 142
Brunasso, A. M. G., Puntoni, M., Gulia, A., & Massone, C. (2011) · Rheumatology · doi:10.1093/rheumatology/ker190 · Cited by 141
Berthelsen, B. G., Fjeldsøe-Nielsen, H., Nielsen, C. T., & Hellmuth, E. (2010) · Rheumatology · doi:10.1093/rheumatology/keq185 · Cited by 125
Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship.
Carter, J. D., Valeriano, J., & Vasey, F. B. (2006) · PubMed · Cited by 111
Snast, I., Atzmony, L., Braun, M., Hodak, E., & Pavlovsky, L. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.01.037 · Cited by 101
Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management
Viganò, M., Degasperi, E., Aghemo, A., Lampertico, P., & Colombo, M. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.646986 · Cited by 98
Tsai, T., Ho, V., Song, M. W., Szapary, P. O., Kato, T., Wasfi, Y. S., Li, S., Shen, Y., Leonardi, C., on behalf of the PHOENIX 1, P. 2., et al. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.11142.x · Cited by 96
Mikulska, M., Nicolini, L. A., Signori, A., Rivoli, G., Bono, V. D., Raiola, A. M., Grazia, C. D., Dominietto, A., Varaldo, R., Ghiso, A., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12611 · Cited by 88
Analysis of 629 pregnancy outcomes in transplant recipients treated with sandimmun
Lamarque, V., Leleu, M. F., Monka, C., & Krupp, P. (1997) · Transplantation Proceedings · doi:10.1016/s0041-1345(97)00458-2 · Cited by 82
Spontaneous abortion during ustekinumab therapy
Fotiadou, C., Lazaridou, E., Sotiriou, E., & Ioannides, D. (2012) · Journal of Dermatological Case Reports · doi:10.3315/jdcr.2012.1116 · Cited by 63
Systemic Treatments for Severe Pediatric Psoriasis
Marqueling, A. L., & Cordoro, K. M. (2013) · Dermatologic Clinics · doi:10.1016/j.det.2012.12.005 · Cited by 52
Koskinas, J. S., Tampaki, M., Doumba, P. P., & Rallis, E. A. (2012) · British Journal of Dermatology · doi:10.1111/bjd.12120 · Cited by 47
Etanercept therapy in patients with autoimmunity and hepatitis C
Khanna, M., Shirodkar, M., & Gottlieb, A. B. (2003) · Journal of Dermatological Treatment · doi:10.1080/09546630310020470 · Cited by 42
Mycobacterial infections in organ transplant recipients
John, G. T. (2002) · Seminars in Respiratory Infections · doi:10.1053/srin.2002.36445 · Cited by 38
Saeki, H., Ito, T., Hayashi, M., Fukuchi, O., Umezawa, Y., Nobeyama, Y., Teruya, K., & Nakagawa, H. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12531 · Cited by 37
Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease
Sansone, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i13.3516 · Cited by 35
Detection and management of latent tuberculosis infections before biologic therapy for psoriasis
Amerio, P., Amoruso, G. F., Bardazzi, F., Campanati, A., Cassano, N., Conti, A., Gisondi, P., Guarneri, C., Mazzotta, A., Piaserico, S., et al. (2012) · Journal of Dermatological Treatment · doi:10.3109/09546634.2011.654107 · Cited by 32
Winger, E. E., & Reed, J. L. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090141 · Cited by 27
Apremilast for a psoriasis patient with HIV and hepatitis C
Reddy, S. P., Shah, V. V., & Wu, J. J. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14301 · Cited by 26
Clarke, D. O., Hilbish, K. G., Waters, D. G., Newcomb, D. L., & Chellman, G. J. (2015) · Reproductive Toxicology · doi:10.1016/j.reprotox.2015.10.008 · Cited by 20
Nuzzo, S. D., Boccaletti, V., Fantini, C., Cortelazzi, C., Missale, G., Fabrizi, G., Lotti, T., Hercogova, J. T., & Pagliarello, C. (2015) · Dermatology · doi:10.1159/000439587 · Cited by 19
Raddadi, A. A., & Damanhoury, Z. B. (1999) · PubMed · Cited by 19
Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient.
Lindsey, S. F., Weiss, J., Lee, E. S., & Romanelli, P. (2014) · PubMed · Cited by 17
Safety of secukinumab in hepatitis B virus
Bevans, S. L., Mayo, T. T., & Elewski, B. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14608 · Cited by 17
Psoriasis treated with ustekinumab in a patient with hepatitis C
Abuchar, A., Vitiello, M., & Kerdel, F. A. (2013) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2011.04876.x · Cited by 15
Photosensitive psoriasis in a vitiligo patient
Torchia, D., Margherita, T., & Fabbri, P. (2006) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2006.00201.x · Cited by 13
Drug-Induced Liver Injury Caused by Adalimumab: A Case Report and Review of the Bibliography
Frider, B., Bruno, A., Ponte, M. L., & Amante, M. F. (2013) · Case Reports in Hepatology · doi:10.1155/2013/406901 · Cited by 12
Cited by
Novel therapeutic approaches to psoriasis and risk of infectious disease
Motolese, A., Ceccarelli, M., Macca, L., Li Pomi, F., Ingrasciotta, Y., Nunnari, G., & Guarneri, C. (2022) · Biomedicines · doi:10.3390/biomedicines10020228 · Cited by 35
“Serious opportunistic infections were comparable between placebo and apremilast in trials and no cases of LTBI reactivation have been showed so far in patients treated with apremilast [51,52].”
BackgroundInfluentialTwo-year US Pharmacovigilance report on Brodalumab
Lebwohl, M., Leonardi, C., Wu, J. J., Armstrong, A., Rawnsley, N., Merchant, M., Alexander, B., & Jacobson, A. (2021) · Dermatology and Therapy · doi:10.1007/s13555-020-00472-x · Cited by 24
Self-citation
Metadata
- Authors
- Kaushik, S. B., & Lebwohl, M. G.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 80
- Issue
- 1
- Pages
- 43-53
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W2941146433
- Cited by
- 268
- References
- 50
- FWCI
- 12.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.